Do analysts rate INAB or BYSI?

IN8bio currently has a consensus target price of $4.00, suggesting a potential upside of 114.71%. Given IN8bio's stronger consensus rating and higher possible upside, equities analysts plainly believe IN8bio is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is INAB or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% BeyondSpring N/A N/A -14.00%

Do analysts prefer IZTC or INAB?

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 114.71%. Given IN8bio's stronger consensus rating and higher probable upside, analysts plainly believe IN8bio is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, IZTC or INAB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A IN8bio N/A N/A -$19.44M -$2.61 N/A

Is IZTC or INAB more profitable?

Invizyne Technologies' return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A IN8bio N/A -96.39% -80.18%

Does the media prefer IZTC or INAB?

In the previous week, IN8bio had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 3 mentions for IN8bio and 1 mentions for Invizyne Technologies. IN8bio's average media sentiment score of 0.84 beat Invizyne Technologies' score of 0.75 indicating that IN8bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invizyne Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IN8bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, INAB or ENTX?

Entera Bio has higher revenue and earnings than IN8bio. Entera Bio is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$2.61 N/A Entera Bio $40K 1,593.50 -$11.44M -$0.27 N/A

Is INAB or ENTX more profitable?

Entera Bio's return on equity of -83.31% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% Entera Bio N/A -83.31% -70.83%

Does the media refer more to INAB or ENTX?

In the previous week, IN8bio and IN8bio both had 3 articles in the media. IN8bio's average media sentiment score of 0.84 beat Entera Bio's score of 0.62 indicating that IN8bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IN8bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, INAB or CING?

Cingulate is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$2.61 N/A Cingulate N/A N/A -$22.45M -$4.23 N/A

Is INAB or CING more profitable?

IN8bio's return on equity of -96.39% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% Cingulate N/A -365.15% -158.55%

Is IMA or INAB more profitable?

ImageneBio's return on equity of -38.96% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.96% -34.60% IN8bio N/A -96.39% -80.18%

Does the media favor IMA or INAB?

In the previous week, IN8bio had 1 more articles in the media than ImageneBio. MarketBeat recorded 3 mentions for IN8bio and 2 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.94 beat IN8bio's score of 0.84 indicating that ImageneBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IN8bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IN8bio (INAB) Competitors

$1.86 +0.06 (+3.50%)

As of 03:24 PM Eastern

Compare

INAB vs. BYSI, IZTC, ENTX, CING, and IMA

Should you buy IN8bio stock or one of its competitors? MarketBeat compares IN8bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IN8bio include BeyondSpring (BYSI), Invizyne Technologies (IZTC), Entera Bio (ENTX), Cingulate (CING), and ImageneBio (IMA). These companies are all part of the "pharmaceutical products" industry.

How does IN8bio compare to BeyondSpring?

IN8bio (NASDAQ:INAB) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

BeyondSpring has higher revenue and earnings than IN8bio. BeyondSpring is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
BeyondSpring	$1.75M	39.95	-$1.01M	-$0.14	N/A

IN8bio has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

BeyondSpring's return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
BeyondSpring	N/A	N/A	-14.00%

IN8bio currently has a consensus target price of $4.00, suggesting a potential upside of 114.71%. Given IN8bio's stronger consensus rating and higher possible upside, equities analysts plainly believe IN8bio is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, IN8bio had 2 more articles in the media than BeyondSpring. MarketBeat recorded 3 mentions for IN8bio and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.89 beat IN8bio's score of 0.84 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
IN8bio	Positive
BeyondSpring	Very Positive

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 14.5% of IN8bio shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

BeyondSpring beats IN8bio on 8 of the 14 factors compared between the two stocks.

How does IN8bio compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

In the previous week, IN8bio had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 3 mentions for IN8bio and 1 mentions for Invizyne Technologies. IN8bio's average media sentiment score of 0.84 beat Invizyne Technologies' score of 0.75 indicating that IN8bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invizyne Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IN8bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.1% of IN8bio shares are held by institutional investors. 14.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 114.71%. Given IN8bio's stronger consensus rating and higher probable upside, analysts plainly believe IN8bio is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

Invizyne Technologies' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
IN8bio	N/A	-96.39%	-80.18%

Summary

IN8bio beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

How does IN8bio compare to Entera Bio?

IN8bio (NASDAQ:INAB) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Entera Bio has higher revenue and earnings than IN8bio. Entera Bio is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
Entera Bio	$40K	1,593.50	-$11.44M	-$0.27	N/A

IN8bio has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

Entera Bio's return on equity of -83.31% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
Entera Bio	N/A	-83.31%	-70.83%

In the previous week, IN8bio and IN8bio both had 3 articles in the media. IN8bio's average media sentiment score of 0.84 beat Entera Bio's score of 0.62 indicating that IN8bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IN8bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IN8bio currently has a consensus target price of $4.00, suggesting a potential upside of 114.71%. Entera Bio has a consensus target price of $9.00, suggesting a potential upside of 594.98%. Given Entera Bio's higher probable upside, analysts clearly believe Entera Bio is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 14.5% of IN8bio shares are owned by insiders. Comparatively, 10.4% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Entera Bio beats IN8bio on 7 of the 11 factors compared between the two stocks.

How does IN8bio compare to Cingulate?

IN8bio (NASDAQ:INAB) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

IN8bio's return on equity of -96.39% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
Cingulate	N/A	-365.15%	-158.55%

IN8bio has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.81, meaning that its share price is 181% less volatile than the broader market.

In the previous week, Cingulate had 8 more articles in the media than IN8bio. MarketBeat recorded 11 mentions for Cingulate and 3 mentions for IN8bio. Cingulate's average media sentiment score of 0.95 beat IN8bio's score of 0.84 indicating that Cingulate is being referred to more favorably in the news media.

Company	Overall Sentiment
IN8bio	Positive
Cingulate	Positive

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 14.5% of IN8bio shares are owned by company insiders. Comparatively, 4.3% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cingulate is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

IN8bio presently has a consensus price target of $4.00, suggesting a potential upside of 114.71%. Cingulate has a consensus price target of $28.33, suggesting a potential upside of 586.54%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

IN8bio beats Cingulate on 8 of the 13 factors compared between the two stocks.

How does IN8bio compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

ImageneBio has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, IN8bio has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market.

IN8bio has lower revenue, but higher earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	79.74	-$45.35M	-$5.79	N/A
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

ImageneBio's return on equity of -38.96% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
IN8bio	N/A	-96.39%	-80.18%

In the previous week, IN8bio had 1 more articles in the media than ImageneBio. MarketBeat recorded 3 mentions for IN8bio and 2 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.94 beat IN8bio's score of 0.84 indicating that ImageneBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IN8bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 5.9% of ImageneBio shares are owned by company insiders. Comparatively, 14.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ImageneBio presently has a consensus target price of $26.50, indicating a potential upside of 342.40%. IN8bio has a consensus target price of $4.00, indicating a potential upside of 114.71%. Given ImageneBio's higher probable upside, equities research analysts plainly believe ImageneBio is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

ImageneBio and IN8bio tied by winning 7 of the 14 factors compared between the two stocks.

Get IN8bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INAB vs. The Competition

Export

Metric	IN8bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.32M	$3.39B	$6.41B	$12.57B
Dividend Yield	N/A	2.28%	2.75%	5.26%
P/E Ratio	-0.71	18.88	21.27	26.27
Price / Sales	N/A	331.50	560.98	113.99
Price / Cash	N/A	125.26	43.49	56.90
Price / Book	0.81	7.26	10.58	7.32
Net Income	-$19.44M	$24.20M	$3.56B	$336.95M
7 Day Performance	11.56%	3.82%	2.91%	3.44%
1 Month Performance	23.38%	9.27%	6.26%	7.18%
1 Year Performance	-59.52%	63.27%	36.44%	37.43%

IN8bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INAB IN8bio	3.9071 of 5 stars	$1.86 +3.5%	$4.00 +114.7%	-57.7%	$18.32M	N/A	N/A	20
BYSI BeyondSpring	0.1994 of 5 stars	$1.58 +0.6%	N/A	+0.9%	$64.97M	$1.75M	N/A	80
IZTC Invizyne Technologies	N/A	$9.92 +5.5%	N/A	-29.2%	$62.02M	N/A	N/A	29	Gap Up
ENTX Entera Bio	4.0105 of 5 stars	$1.26 +1.2%	$9.00 +617.1%	-33.5%	$61.77M	$40K	N/A	20	News Coverage
CING Cingulate	3.3501 of 5 stars	$4.57 +2.2%	$28.33 +520.0%	+8.5%	$61.56M	N/A	N/A	20	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INAB) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IN8bio (INAB) Competitors